Camden National Corporation’s Bristol-Myers Squibb BMY Stock Holding History

Camden National Corporation’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$445K	Buy	+7,046	New	+$438K	0.09%	95

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Camden National Corporation's BMY Position: Q1 2021 in Review

Camden National Corporation opened a new position in Bristol-Myers Squibb (BMY) in Q1 2021: 7,046 shares worth $445K. The stake represents 0.09% of the portfolio and ranks #95 among its holdings.

2,369 funds tracked by Wall St. Rank hold BMY as of Q1 2021.

Camden National Corporation held 7,046 shares of Bristol-Myers Squibb worth $445K as of Q1 2021.
Bristol-Myers Squibb was a new Camden National Corporation position in Q1 2021.
Bristol-Myers Squibb made up 0.09% of Camden National Corporation's portfolio in Q1 2021, its #95 holding.
2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.

Based on Camden National Corporation's 13F filing for Q1 2021, filed 12 May 2021.